Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDimerix Ltd

Dimerix Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.215 AUD -0.01 ( 2.27%)
Last update at 2026-11-11T05:10:00Z
VOLUME
1108379
Market Cap
126.08M

Momentum Score

…

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.21
Low
0.23
High
52 Week Price Range
0.16
Low
0.67
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Dimerix Ltd is an Australian clinical-stage biopharmaceutical company developing novel therapeutics through a proprietary discovery platform, with lead programs progressing in clinical development. Long-term growth may benefit from positive trial readouts, regulatory approvals and licensing or partnership deals that could support commercialization and market access. Investors may find the company attractive because clinical progress and strategic collaborations could materially de-risk value.

The main investment risks are clinical and regulatory failure, ongoing funding requirements and dilution, limited revenue until approvals, and competition from larger pharmaceutical companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.22
Dividend Yield
-
Revenue TTM
6.35M
Revenue Per Share
0.01
Gross Profit TTM
6.35M
Debt / Equity
-0.02
ROE
-594.54%
Net Debt
-15.92M
ROCE
-75.24%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -36.55M -31.68M -17.08M -13.80M -10.49M
Net income -29.81M -13.25M -17.07M -13.80M -10.49M
Selling general administrative - 4.89M 3.12M 2.17M 2.39M
Selling and marketing expenses - - 1.42M 0.07M -
Gross profit 4.21M 1.25M 0.58M 8.98M -
Reconciled depreciation - 0.12M 0.05M 0.06M 0.05M
Ebit -37.18M -36.34M -25.01M -22.82M -16.96M
Ebitda -37.04M -36.22M -24.96M -22.77M -16.91M
Depreciation and amortization 0.14M 0.12M 0.05M 0.06M 0.05M
Operating income -37.18M -36.34M -25.24M -13.84M -16.96M
Other operating expenses 41.53M 37.60M 25.64M 22.82M 16.96M
Interest expense - - - - 0.00M
Tax provision - -18.43M 0.00M 0.00M 0.00M
Interest income - 0.33M 0.18M 0.04M 0.00M
Net interest income - 0.33M 0.18M 0.04M 0.00M
Income tax expense -6.74M -18.43M -7.93M -0.04M 0.00M
Total revenue 4.35M 1.25M 0.58M 8.98M 0.00M
Total operating expenses 41.39M 37.60M 25.64M 22.82M 16.96M
Cost of revenue 0.14M - - - -
Total other income expense net 0.62M 0.33M 8.16M 8.98M 6.47M
Net income from continuing ops - -13.25M -17.08M -13.80M -10.49M
Net income applicable to common shares - -13.25M -17.08M -13.80M -10.49M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 58.59M 91.18M 32.08M 17.76M 16.50M
Other current assets 0.29M - 0.26M 0.02M 0.07M
Total liab 73.35M 77.80M 13.89M 11.79M 2.07M
Total stockholder equity -14.76M 13.38M 18.19M 5.96M 14.42M
Other current liab 1.14M 4.23M 2.40M 6.62M 0.91M
Common stock 91.18M - 83.38M 55.49M 50.90M
Capital stock - 90.92M 83.38M 55.49M 50.90M
Retained earnings -112.24M -82.43M -69.18M -52.10M -38.30M
Other liab - - - 0.04M 0.03M
Cash 16.15M 68.28M 22.14M 7.99M 9.63M
Cash and equivalents - - - 7.99M 9.63M
Total current liabilities 9.18M 22.16M 3.36M 11.76M 2.02M
Current deferred revenue 5.64M - 0.57M -5.96M -0.05M
Net debt -15.92M - -21.99M -2.03M -9.56M
Short term debt 0.12M - 0.08M 5.96M 0.05M
Short long term debt - - - 5.94M -
Short long term debt total 0.23M - 0.15M 5.96M 0.07M
Other stockholder equity - - - -3.39M -12.60M
Property plant equipment - - - 0.01M 0.01M
Total current assets 35.07M 72.18M 31.92M 17.75M 16.49M
Net tangible assets - - - 5.96M 14.42M
Net receivables 18.63M - 9.52M 9.55M 6.39M
Inventory - - - 0.18M 0.40M
Accounts payable 2.28M 14.08M 0.31M 5.14M 1.11M
Accumulated other comprehensive income 6.31M - 3.98M 2.57M 1.83M
Non currrent assets other - - - -0.01M -0.01M
Non current assets total 23.52M 19.00M 0.16M 0.01M 0.01M
Capital lease obligations - 0.10M 0.15M 0.02M 0.07M
Long term debt total - - - 0.00M 0.02M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.02M -0.02M -0.00M -0.01M
Change to liabilities - - - 3.64M -0.92M
Total cashflows from investing activities -0.00M -0.02M -0.02M -0.00M -0.01M
Net borrowings - - -2.84M 6.29M -1.75M
Total cash from financing activities 0.12M 7.42M 21.17M 11.07M 17.69M
Change to operating activities - - - 0.06M -0.25M
Net income -29.81M -13.25M -17.08M -13.80M -10.49M
Change in cash -52.13M 46.14M 14.15M -1.64M 4.38M
Begin period cash flow 68.28M 22.14M 7.99M 9.63M 5.25M
End period cash flow 16.15M 68.28M 22.14M 7.99M 9.63M
Total cash from operating activities -51.81M 39.05M -7.00M -12.73M -13.44M
Issuance of capital stock - 7.55M 25.71M 8.72M 20.68M
Depreciation 0.14M - 0.05M 0.06M 0.05M
Other cashflows from investing activities - - - - 0.00M
Dividends paid - - - - 0.00M
Change to account receivables -14.61M 5.63M 0.04M -3.17M -2.34M
Sale purchase of stock - 7.55M -1.40M -0.44M -1.24M
Other cashflows from financing activities -0.15M -0.02M -0.29M 2.79M -0.05M
Change to netincome - - - 0.49M 0.51M
Capital expenditures 0.00M 0.02M 0.02M 0.00M 0.01M
Change in working capital -24.03M 50.59M 7.97M -3.17M -2.34M
Stock based compensation - - 1.41M 0.07M 0.13M
Other non cash items 1.89M -11.54M 0.64M 1.02M -3.00M
Free cash flow -51.81M 39.03M -7.02M -12.73M -13.45M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DXB
Dimerix Ltd		 -0.01
2.27%		 0.21 - 10.78 19.84 24.45 23.94 -1.94
CSL
CSL Ltd		 0.95
0.47%		 201.68 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 0.22
1.59%		 14.02 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.24
0.99%		 23.96 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.05
2.40%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Dimerix Ltd

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.

425 Smith Street, Fitzroy, VIC, Australia, 3065

1300 813 321

https://dimerix.com

15

Name Title Year Born
Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. CEO, MD & Director NA
Dr. Ashish Soman M.B.A., M.D., MBBS Chief Medical Officer NA
Mr. Hamish George B.Com., C.A. CFO & Company Sec. NA
Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D. Chief Scientific Advisor NA
Ms. Elizabeth McCall B.Com(Hons), B.Juris, BJURIS, GAICD, L.L.B., LLB. Bus. Devel. Officer NA
Mr. Hamish George B.Com., C.A. CFO & Company Secretary NA
Dr. David Everett Fuller BPharm, M.D., MBBS Chief Medical Officer 1964
Mr. Robert Shepherd Chief Commercialisation Officer NA
Mr. Hamish George B.Com., C.A. CFO & Company Secretary NA
Dr. David Everett Fuller BPharm, M.D., MBBS Chief Medical Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 39.00
+13.97%
QNC
CAD 1.52
+13.43%
KEEL
CAD 3.02
+11.21%
SOIL
CAD 8.19
+9.35%
CLS
CAD 345.20
+8.31%
GSY
CAD 38.09
-15.28%
BYD
CAD 110.19
-11.83%
CFW
CAD 6.45
-11.64%
LAC
CAD 2.47
-8.18%
BSX
CAD 0.74
-6.33%

Equity Sectors*

  • Basic Materials

    -0.08%

  • Communication Services

    +0.12%

  • Consumer Cyclical

    -0.62%

  • Consumer Defensive

    -0.47%

  • Energy

    +1.93%

  • Financial Services

    -0.06%

  • Healthcare

    +2.30%

  • Industrials

    +1.50%

  • Real Estate

    -0.36%

  • Technology

    +2.52%

  • Utilities

    +0.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…